Perampanel
As of the edition of 20 October 2026, Perampanel is a small molecule: marketed, first approved in 2012 (EU); acts on GRIA1, GRIA2 and GRIA3 and 1 more; US protection ended in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Fycompa
- First approved
- 23 July 2012 (EU)
- Approvals on record
- 21 in 6 regions
- Holder of the most recent approval
- Eisai; 3 holders in all
- Registered trials
- 90, 16 stopped early
- Disease areas
- Nervous system; Mental health; Nutrition and metabolism; Cancer; Inherited and neonatal; Heart and blood vessels
US protection
US protection ended in 2026.
The last listed US drug-substance patent ended in 2026. The application that gives this date is held by Angelini Pharma.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product7 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 7 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Perampanel.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 22 | 13 | 0 | 2 |
| Phase 1 | 13 | 12 | 1 | 0 |
| Phase 2 | 27 | 18 | 2 | 5 |
| Phase 3 | 15 | 11 | 0 | 4 |
| Phase 4 | 13 | 7 | 0 | 5 |
| All trials | 90 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eisai | Applicant and Lead sponsor of trials | 2003 to now |
| Angelini Pharma | Acquired holder | 2023 to now |